Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1642 1672 1681 1684 1686
This examiner grants 59% of resolved cases
Mary K. Zeman is an examiner in Art Unit 1631 of Tech Center 1600. She has 546 resolved cases and an allowance rate of 59.0 percent. This 59.0 percent rate suggests a chance of success for patent applicants. The median days to allowance is 1460. This 1460-day figure is a factor for timeline expectations. Practitioners should communicate this metric to their clients for planning purposes in Tech Center 1600.
The interview lift of 34.0 percent indicates that interviews are an effective way to move toward an allowance. This 34.0 percent lift is a metric for practitioners to consider when navigating Art Unit 1631. With 546 resolved cases, the 59.0 percent allowance rate is an indicator of the examiner's disposition. The 34.0 percent lift suggests that direct engagement can change the path to a grant. The 1460-day median is a reference point for the duration of the examination process.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18038453 | BIOMARKERS FOR DIAGNOSING PROSTATE CANCER, COMBINATION THEREOF, AND USE THEREOF | Non-Final OA | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 17591355 | Systems and Methods for Sequencing T Cell Receptors and Uses Thereof | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17814042 | MOLECULAR LABEL COUNTING ADJUSTMENT METHODS | Non-Final OA | Becton, Dickinson And Company |
| 17407000 | METHODS AND SYSTEMS FOR DETERMINING THE CELLULAR ORIGIN OF CELL-FREE DNA | Final Rejection | GUARDANT HEALTH, INC. |
| 17602895 | COMPREHENSIVE DETECTION OF SINGLE CELL GENETIC STRUCTURAL VARIATIONS | Non-Final OA | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
| 18274433 | DEVICE FOR PREDICTING DRUG-TARGET INTERACTION BY USING SELF-ATTENTION-BASED DEEP NEURAL NETWORK MODEL, AND METHOD THEREFOR | Non-Final OA | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18484268 | DETECTING AND CORRECTING METHYLATION VALUES FROM METHYLATION SEQUENCING ASSAYS | Non-Final OA | Illumina, Inc. |
| 17968167 | METHOD FOR DETERMINING CELL CLONALITY | Non-Final OA | ARES TRADING S.A. |
| 17572170 | PRIMER DESIGN USING INDEXED GENOMIC INFORMATION | Final Rejection | NOBLIS, INC. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy